RO 435054

Drug Profile

RO 435054

Latest Information Update: 14 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class Antiplatelets; Small molecules; Vascular disorder therapies
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis; Unstable angina pectoris

Most Recent Events

  • 16 Aug 2002 No development reported - Preclinical for Thrombosis in Switzerland (unspecified route)
  • 16 Aug 2002 No development reported - Preclinical for Unstable angina pectoris in Switzerland (unspecified route)
  • 08 Sep 1998 A preclinical study has been added to the Ischaemic Heart Disease and Thromboses pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top